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Abstract
Purpose. To de® ne the maximally tolerated dose (MTD) of ifosfamide when given with G-CSF on an every other week
schedule, and to de® ne the MTD of edatrexate that can be given every two weeks with an intense schedule of ifosfamide.
Patients and Methods. Forty-one patients with metastatic or unresectable, locally advanced sarcoma participated in this
2-step phase I trial.The starting dose of ifosfamide was 10 gm/m
2 given by continuous intravenous infusion over 4 days every
2 weeks.When the MTD was de® ned, edatrexate, beginning at a dose of 40 mg/m
2 intravenously every 2 weeks was added
in subsequent cohorts of patients.
Results. Myelosuppression was the most prominent toxicity. Fatigue, nausea, and vomiting were observed in the majority
of patients. Ifosfamide 12 gm/m
2 given every 2 weeks approached or exceeded the MTD. Edatrexate 100 mg/m
2 could be
given safety as an intravenous bolus with ifosfamide 10 gm/m
2 every 2 weeks. Therapeutic responses were observed in
patients with measurable disease.
Conclusions. This study demonstrates the feasibility of administering a dose-intense schedule of ifosfamide alone or ifosfa-
mide with edatrexate that might be applied in the adjuvant or neo-adjuvant setting.
Introduction
The activity of ifosfamide in soft tissue sarcoma has
been recognized since 1973, but the development of
this drug was hindered by its urothelial toxicity. The
introduction of the disul® de uroprotective agent,
mesna, permitted extensive clinical evaluation of ifos-
famide. In a large phase II trial, the response to ifos-
famide 8 gm/m
2 was 21% among 124 patients with
sarcoma.
1In a randomized phase II trial, the response
to ifosfamide 5 gm/m
2 was 24% among patients with
soft tissue sarcoma who had not previously been
treated with chemotherapy.
2 Response to its analog,
cyclophosphamide, at a dose of 1.5 gm/m
2 was only
9%, in spite of greater myelosuppression in the latter
group of patients.
A dose± response relationship has been claimed for
ifosfamide in patients with soft tissue sarcoma.
3 In
most studies of high dose ifosfamide, the drug has
been given at increased doses every 3 to 4 weeks.
Colony stimulating factors, such as G-CSF
3 and
GM-CSF,
4,5 reduce the myelosuppressive toxicity of
high dose ifosfamide, but dose-dependent renal and
neurologic toxicities limit the dose of ifosfamide
that can be given per cycle.
6 Most investigators
have attempted to increase dose-intensity by
increasing the total dose of ifosfamide given over
several days every 3 weeks. In this study, we explored
intensi® cation of ifosfamide therapy by increasing
the frequency of ifosfamide administration to every
2 weeks.
As part of our phase II program for patients with
soft tissue sarcoma, we observed 5 major objective
responses to edatrexate among 35 patients with soft
tissue sarcoma.
7 The starting dose of edatrexate in
that trial was 80 mg/m
2 weekly, but patient tolerance
was variable, and weekly doses ranged from 50 to
120 mg/m
2. Edatrexate also has shown activity in
patients with sarcoma in an Eastern Cooperative
Oncology Group phase II trial.
8 In addition,
edatrexate has demonstrated antineoplastic activity
in human sarcoma cell lines in our laboratory.
9
Preclinical data have suggested synergy between
edatrexate and alkylating agents in several murine
tumor models, including T241 sarcoma.
10 We
reasoned that the combination of edatrexate and ifos-
famide might have useful clinical efficacy in patients
with sarcoma. Furthermore, an active, dose-intense
ifosfamide-based combination might be a useful
component of neoadjuvant or adjuvant chemotherapy
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A two-stage phase I trial of high dose ifosfamide,
therefore, was conducted. First, the maximum toler-
ated dose (MTD) of ifosfamide given by continuous
intravenous infusion over 4 days every other week
with G-CSF support was determined.We then sought
the MTD of edatrexate that could be given safely
every two weeks with an intense schedule of ifosfa-
mide.We now report the results of this investigation.
Patients, materials and methods
The protocol was reviewed and approved by the
Institutional Review Board of Memorial Sloan-
Kettering Cancer Center.
Patients
This study was designed as a disease-speci® c phase I
trial for patients with metastatic or unresectable,
locally advanced sarcoma. Histologic con® rmation of
sarcoma by the Department of Pathology of Memo-
rial Hospital was necessary. The trial was limited to
patients who had not previously been treated with
ifosfamide, and those with not more than one previous
chemotherapy regimen. Patients could not have
received chemotherapy or therapeutic irradiation
during the 4 weeks before their ® rst dose of ifosfa-
mide. A Karnofsky performance status of 60% or
greater was required, as was a WBC‡ 4000/mm
3,
platelet count‡ 150,000/mm
3, serum
bilirubin<1.5 mg/dl, and serum creatinine<1.5 or
creatinine clearance‡ 60 mg/min/1.73m
2. Patients with
clinically evident third space ¯ uid (ascites or pleural
effusions) were excluded from this trial.
All patients had a physical examination, a chest
radiograph, and appropriate imaging studies to
establish extent of disease and tumor measurements
when possible. Measurable or evaluable disease was
not required, however.
Therapeutic agents
Ifosfamide and mesna were purchased as Ifex and
Mesnex, respectively (Mead Johnson Oncology
Products, Evansville, IN). Ifosfamide was
reconstituted with Sterile Water for Injection USP to
yield a 50 mg/ml solution.The daily prescribed dose
of ifosfamide was mixed in 1 L of 0.45% NaCl, and
was administered intravenously over a 24 hour period.
A dose of mesna equal to the ifosfamide dose was
added to the IV bag containing the ifosfamide.
The Division of Cancer Treatment (National
Cancer Institute, Bethesda, MD) supplied edatrexate
as a lyophilized sterile powder in 50 mg vials.
Edatrexte was dissolved in 4 ml sterile Normal Saline
USP to yield a solution of edatrexate 12.5 mg/ml.
The ® nal dose of edatrexate was diluted in a 50 ml
bag of Normal Saline USP, and administered
intravenously over 25± 30 min.
Recombinant human ® lgrastim (G-CSF,
Neupogen) for this study was provided by Amgen,
Inc. (Thousand Oaks, CA) under an agreement with
Memorial Sloan-Kettering Cancer Center.
Treatment plan
Signed informed consent was obtained from all
patients who participated in this trial.Treatment was
given in the hospital. Oral or intravenous hydration
was administered to maintain a urine output of at
least 2000 ml/24 h during ifosfamide infusion. The
ifosfamide and mesna were administered by
continuous 24-hour intravenous infusion over 4
consecutive days every 2 weeks. Mesna was not
continued beyond the completion of the ifosfamide
infusion. Ifosfamide therapy was interrupted for
hematuria (RBC greater than 11 RBC/hpf), an
increase in serum creatinine>1.0 mg/dl, or for clini-
cally signi® cant neurological side effects. The initial
dose of ifosfamide was 10 gm/m
2. In patients who
received edatrexate, this agent was given on the ® rst
day of each cycle. The initial dose of edatrexate was
40 mg/m
2.
G-CSF (5m /kg/day) was self-administered
subcutaneously daily beginning 48 hours after the
completion of the ifosfamide infusion, and was
administered until the recovering ANC was ‡ 1500/
mm
3. Subsequent doses of ifosfamide were not
administered within 24 hours of G-CSF injection.
The 4-day course of therapy followed by G-CSF was
de® ned as a cycle of therapy.
If on day 15 the WBC was <4000/mm
3 the ANC
was <1500/mm
3 or the platelet count was <150,000/
mm
3, or if grade 2 or greater mucositis was present,
chemotherapy was held one week. If toxicity had not
resolved by day 21, treatment was held one additional
week. Patients were taken off study if hematologic
recovery was delayed beyond this time. At least 3
patients were to be treated at each dose level. Dose
escalation within individual patients was not
permitted. If dose-limiting toxicity was seen in the
initial 3 patients at a given dose level, additional
patients were added to further evaluate the toxicity.
In the original plan, the maximum tolerated dose
(MTD) was de® ned on the basis of duration of myelo-
suppression, with more than 5 days of grade 4 neutro-
penia constituting dose-limiting toxicity. During the
study it became clear that the non-hematologic
toxicity likely to be associated with that degree of
myelosuppression would be unacceptable.Thus, since
our objective was to treat patients every 2 weeks, any
toxicity that prevented recycling of treatment on day
15 (e.g.ANC<1500/mm
3or platelet count<150,000/
mm
3) was accepted as dose-limiting, and the MTD
was de® ned as the highest dose level at which the
majority of patients could be recycled on day 15.
This was a two-part study. First, the MTD and
schedule for the administration of ifosfamide every 2
weeks was de® ned. Additional cohorts of patients
122 E.S. Casper et al.were then treated with escalating doses of edatrexate
in combination with ifosfamide to determine the
MTD of edatrexate for use in combination. One dose
below the MTD of ifosfamide de® ned in the ® rst
part of the study was to have been used as the constant
in determining the MTD for edatrexate in the second
part of the study.
Evaluation during study
Patients were followed until dose-limiting toxicity
precluded further therapy, or until progression of
disease was observed.An automated CBC and platelet
count was performed twice weekly. Physical examina-
tion and assessment of toxicity was done before each
cycle of ifosfamide. A biochemical pro® le including
electrolytes, BUN, creatinine, calcium, phosphorus,
and hepatic enzymes was obtained every 2 weeks.
Measurement of indicator lesion(s) was performed at
least every eight weeks for patients with measurable
disease.
Criteria for therapeutic response and toxicity
The NCI Common Toxicity Criteria were used in
this trial.Therapeutic response was not the principal
endpoint of this trial. However, for those patients
who had measurable disease, the criteria of the Adult
Intergroup Soft-Tissue Sarcoma Committee were
applied.
11 The duration of response was measured
from the ® rst day of therapy. Unequivocal clinical
deterioration as evident from increasing pain, progres-
sive weight loss and falling performance status was
accepted as an indication of disease progression in
the absence of signi® cant change in measured lesions.
In patients with evaluable disease, unequivocal tumor
shrinkage was recorded as improvement.
Results
The characteristics of the 41 patients who participated
in the trial are presented in Table 1.The primary sites
for the 34 patients with non-osseous sarcoma are
listed inTable 2. All patients had a Karnofsky perform-
ance status of 70% or greater, and 78% had no
previous chemotherapy. With the exception of one
patient whose prior therapy was only paclitaxel, the
previously treated patients had all been treated with
doxorubicin or a doxorubicin-based combination.
Two patients were inevaluable for hematologic
toxicity. One had acute central nervous system toxicity
during his infosfamide infusion, and therapy was
discontinued. Another was ineligible because he was
found to have a pleural effusion shortly after receiving
his ® rst doses of therapy. All but 3 evaluable patients
had measurable disease. An additional patient was
lost to follow-up before post-treatment tumor
measurements could be made.
Toxicity
Table 3 demonstrates the WBC and platelet toxicity
of the ® rst cycle of chemotherapy for each dose level.
Table 4 outlines the WBC and platelet toxicity
encountered when all cycles administered at each
dose level are included.
The ® rst two levels involved infosfamide without
edatrexate. The starting dose of ifosfamide, 10 gm/
m
2, was well-tolerated. At 12 gm/m
2, one episode of
septicemia was encountered, and sufficient myelosup-
pression was observed in the other 2 patients that a
decision was made to interrupt accrual of patients at
that level. Based on the plan to begin escalation of
edatrexate in combination with a dose of infosfamide
one level below the MTD, the dose of infosfamide
Table 1. Characteristics of 41 patients treated with ifosfamide + G-CSF =/± edatrexate
Age Histologic diagnosis
Median 50 years Soft tissue sarcoma 34
Range 24± 73 years MFH* 8
Leiomyosarcoma 5
Performance status (Karnofsky) Synovial sarcoma 5
MPNT* 3
median 80% Liposarcoma 2
range 70± 90% Epitheliod sarcoma 2
Fibrosarcoma 2
Sex GIST* 2
Hemangiopericytoma 1
Male 25 Spindle Cell 1
Female 16 Rhabdomyosarcoma 1
Chondrosarcoma 1
Prior chemotherapy Undifferentiated 1
Chemotherapy 9
(includes 5 with prior RT) Bone sarcoma 7
No chemotherapy 32 Chondrosarcoma 4
MFH* 1
Osteogenic sarcoma 1
Angiosarcoma 1
*MFH, malignant ® brous histiocytoma; MPNT, malignant peripheral nerve tumor; GIST, gastrointestinal stromal tumor.
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was 8 gm/m
2 every 2 weeks.
It is difficult to draw ® rm conclusions regarding
the relationship between dose and hematologic
toxicity given the wide range of WBC, ANC, platelet
nadirs, and the limited range of ifosfamide doses
studied. Overall, however, there seemed to be a
threshold effect for edatrexate, with doses up to
80 mg/m
2 having little impact on myelosuppression.
With edatrexate 100± 120 mg/m
2, the addition of
edatrexate to a given dose of ifosfamide appeared to
be associated with greater myelotoxicity.
In addition, 15 patients had grade 3 or 4 anemia.
Also anemia was not clearly related to dose level,
although it did appear related to duration of therapy.
All patients experienced alopecia. The incidence of
the other common non-hematologic toxicities, nausea
and vomiting, mucositis, and fatigue is shown in
Table 5. Paralleling the anemia observed, fatigue
appeared to be associated with prolonged duration of
therapy.
In combination with ifosfamide 8 gm/m
2, it was
possible to escalate the dose of edatrexate to 100 mg/
m
2, the phase II dose of that agent for weekly
administration. Therefore, it was elected to treat a
cohort of patients with infosfamide 10 gm/m
2, while
keeping the dose of edatrexate at 100 mg/m
2. When
Table 2. Primary sites of soft tissue sarcoma in 34 patients treated with ifosfamide + G-CSF +/± edatrexate
Extremity/super® cial trunk 20 Head/neck sarcoma 2
MFH* 6 Leiomyosarcoma 1
Synovial sarcoma 5 MPNT 1
Epithlioid 2 Retroperitoneal/pelvic 5
Fibrosarcoma 1 MFH* 2
Liposarcoma 1 Liposarcoma 1
MPNT* 1 MPNT* 1
Leiomyosarcoma 1 GIST* 1
Rhabdomyosarcoma 1 Genitourinary sarcoma 2
Chondrosarcoma 1 Leiomyosarcoma 1
Undifferentiated 1 Spindle Cell 1
Other 1
Cardiac ® brosarcoma 1
Gastrointestinal sarcoma 2 Unknown 2
Leiomyosarcoma 1 Hemangiopericytoma 1
GIST* 1 Leiomyosarcoma 1
Table 3. Response
Soft tissue
sarcoma Bone sarcoma
Complete response 0 1
Partial response 4 1
Minor response 2 0
Stable disease 14 4
Improvement
(evaluable disease)
3 0
Progression of disease 9 0
Not evaluable 2 1
Total 34 7
Table 4. Hematologic toxicity for all cycles of ifosfamide + G-CSF +/± edatrexate
Ifosfamide
(g/m
2)
Edatrexate
(mg/m
3)
Number of
patients
Number of
cycles
Median
WBC nadir
(range)
Median
ANC nadir
(range)
Median
platelet nadir
(range)
Median number
of cycles per
patient (range)
10 0 5 23 0.8 0.22 173 4
(0.1± 46.9) (0.0± 42.8) (62± 327) (3± 6)
12 0 3 7 1.0 0.76 149 2
(0.1± 41.4) (0.0± 35.19) (19± 229) (1± 4)
8 40 5 22 6.6 5.1 162.5 4
(0.7± 18) (0.26± 16.92) (40± 583) (2± 8)
8 60 7 28* 3.6 2.5 145 4
(0.6± 52.8) (0.2± 46.46) (40± 343) (1± 7)
8 80 6 30 1.75 0.95 183 5
(0.4± 9.4) (0.05± 7.9) (108± 345) (1± 7)
8 100 5 17 3.0 1.99 158 2
(0.4± 9.4) (0.05± 7.9) (108± 345) (1± 7)
10 100 5 22 2.0 0.83 95 4
(0.1± 13.6) (0.0± 9.79) (36± 153) (4± 6)
10 120 5 19 1.8 0.48 196 4
(0.4± 6.2) (0.01± 4.85) (37± 298) (1± 7)
*There are 27 evaluable cycles for this dose level.
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dose of edatrexate was escalated to 120 mg/m
2. At
that dose level, the majority of patients could not be
recycled on day 15.Thus, it was concluded that ifos-
famide 10 gm/m
2 with edatrexate 100 mg/m
2 every 2
weeks was a feasible schedule for further testing.
Therapeutic responses
The endpoint of this trial was not therapeutic
response, and phase II conclusions should not be
drawn from a phase I trial. Nonetheless, the
overwhelming majority of patients with soft tissue
sarcoma had received on previous chemotherapy, and
most were evaluable for therapeutic response
(Table 6). It is impossible to evaluate duration of
response, since the length of treatment on this
protocol was generally brief, and therapy after comple-
tion of the protocol treatment was not uniform.
Among the responders, however, one patient with an
angiosarcoma of the pelvis is recorded as having
experienced a clinical PR. He had no viable tumor at
the time of resection after treatment with ifosfamide
plus edatrexate. Although that patient had previously
undergone resection of a metastatic lymph node in
the axilla, he remains free of active sarcoma 48+
months after initiation of ifosfamide therapy. The
response rate was 14% among the 29 patients with
measurable soft tissue sarcoma. In addition, 3 patients
with evaluable, but not strictly measurable disease
experienced unequivocal antitumor responses. This
18% response rate observed among the 32 patients
with evaluable soft tissue sarcoma, and the 24%
response rate overall is similar to that reported for
less intense schedules of ifosfamide alone.
Discussion
The number of drugs with reproducible activity in
patients with soft tissue sarcoma is limited, and the
activity of the most active agents is modest at best. In
large, randomized trials, even combination
chemotherapy yields responses in fewer than 35% of
patients.
12± 14 In the absence of novel drugs with
meaningful clinical activity, it is essential to maximize
the therapeutic bene® t of the available agents.
The antineoplastic activity of ifosfamide in patients
with sarcoma is well-established. In virtually all studies
of ifosfamide or ifosfamide based combinations, the
drug has been given every 3± 4 weeks. Phase II trials of
ifosfamide 5± 8 gm/m
2 yielded responses in 18± 24% of
patients with sarcoma,
1,2 and ifosfamide-based
regimens have become a standard in the treatment of
patients with sarcoma. Drawing phase III conclusions
from phase I or phase II data is unreliable. Taken
together, however, several lines of evidence from phase
I and phase II trials suggest a dose± response relation-
ship for ifosfamide in patients with sarcoma.
High response rates have been reported in trials of
higher doses of ifosfamide.In a small cohort of patients
with synovial cell sarcoma, a 100% CR+PR to infosfa-
mide 14 g/m
2 was reported.
15 In a phase I trial in
which the dose of ifosfamide was escalated from 8 to
18 g/m
2 in sequential cohorts of patients, the maximal
tolerated dose was estimated to be 16 g/m
2.
6 Among
20 patients with sarcoma in that trial, 7 (35%) had
major responses. More recently a 43% CR+PR rate
was reported among 34 evaluable patients who received
ifosfamide 14 gm/m
2 as ® rst-line therapy.
16
In a phase II trial, ifosfamide 14 g/m
2 given over
three days by continuous infusion yielded responses
in 29% of 37 patients with soft tissue sarcoma, and
40% of patients with bone sarcoma.
3Also within that
report was a small cohort of patients in which the
same total dose of ifosfamide was given by intermit-
tent bolus infusion. Five of 11 patients with soft tissue
sarcoma as well as 3 of 3 patients with bone sarcoma
responded, leading the authors to suggest that bolus
therapy is more efficacious than continuous infusion.
Table 5. Number of patients with selected non-hematologic toxicities for all cycles of ifosfamide + G-CSF +/± edatrexate
# of Mucositis Nausea/vomiting Fatigue
Ifos Edam # of pts cycles Grade 2 Grade 3 Grade 2 Grade 3 Moderate Severe
10 0 6 24 0 0 1 0 4 0
12 0 3 7 0 0 1 2 2 1
8 40 5 22 2 0 2 0 2 0
8 60 7 28 2 0 4 0 2 0
8 80 6 30 2 1 1 0 2 0
8 100 5 17 0 2 1 0 3 1
10 100 5 22 2 0 3 0 0 5
10 120 5 19 4 0 2 1 3 2
Table 6. Therapeutic response in 41 patients with sarcoma
Soft tissue
sarcoma Bone sarcoma
Complete response 0 1
Partial response 4 1
Minor response 2 0
Stable disease 14 4
Improvement
(evaluable disease)
3 0
Progression of disease 9 0
Not evaluable 2 1
Total 34 7
Dose-intense ifosfamide and edatrexate in sarcoma 125Pharmacokinetic studies, however, have not shown a
difference in area under the curve for serum ifosfa-
mide or its metabolites, or in ifosfamide metabolites
in urine for 1 hour or bolus infusions of ifosfamide.
27
Further support for a dose± response relationship
comes from studies in which responses to higher doses
of ifosfamide yield responses after progression on
lower doses. For example, ifosfamide 12 g/m
2 yielded
responses in 33% of 36 patients who had progressed
after prior doxorubicin and/or ifosfamide therapy with
less than 8 g/m
2 per cycle.
18 It should be noted that
not all patients in such studies have been shown to be
truly refractory to the lower dosesÐ not all clearly
progressed under treatment.
Finally, high response rates have been seen in
groups of patients treated with intensive anthracycline/
ifosfamide regimens.
19,20 Although the relative
contributions of the high doses of ifosfamide and the
high doses anthracycline in the favorable results in
such trials is unclear, the seeming lack of bene® t for
dose-escalation of doxorubicin in combination with
modest doses of ifosfamide.
21 suggests that it is the
intensity of ifosfamide therapy that is responsible.
Studies of high-dose therapy are likely to be biased
toward younger patients of good performance status.
Furthermore, many investigators have observed that
gastrointestinal leiomyosarcoma is refractory to
ifosfamide-based regimens, and that synovial sarcoma
tends to be particularly responsive to such treat-
ments. Leiomyosarcoma accounts for 35± 50% of
patients in many large phase II or phase III trials.
12,13
Thus, selection of younger patients with extremity
sarcoma for phase I and pilot phase II studies may be
responsible, at least in part, for the differences
observed in response rate among various studies.
A conclusion regarding the relative efficacy of high-
dose ifosfamide requires prospective randomized
trials. In sequential phase II trials, increasing the dose
of doxorubicin from 50 mg/m
2 to 75 mg/m
2 in
combination with infosfamide 5 gm/m
2 appeared to
result in improved efficacy.
22,23Yet, in a randomized
trial by the same group, there was no difference in
response or survival.
21 In the only randomized trial
in which the dose of infosfamide was the major vari-
able, the EORTC reported a response rate of 3%
among patients treated with ifosfamide 5 g/m
2 by
24-hour infusion, but 17% among patients who
received 9 g/m
2 given by 4-hour infusion daily for 3
days.
24The explanation of the low observed response
rate observed in the `standard dose’ arm remains a
matter of speculation, but may be related to the high
proportion of patients with leiomyosarcoma among
the study population. This EORTC trial did not
employ the extremely high doses of ifosfamide
described in other studies, although the results do
support the concept of a dose± response relationship.
The strategy generally employed to increase the
dose-intensity of infosfamide has been to increase
the amount of drug given every three to four weeks.
In our study, the strategy was to increase the frequency
of ifosfamide administration to every two weeks. In
so doing, the total dose administered, expressed in
gm/m
2/week was as high as any previously reported
regimen.Although acute toxicity, including myelosup-
pression, was not immediately dose-limiting, in the
population treated most patients did not receive more
than four cycles of therapy. During the treatment the
majority of patients were able to accept treatment on
schedule. Nonetheless, these patients with their
advanced disease and with a limited life-expectancy
often stated that continuation of this regimen was
inconsistent with their goal of maintaining a good
quality of life. Based on current practice at the time
this study was planned, the treatment was given
entirely on an inpatient basis. This almost certainly
was a confounding factor in patient `burnout’. In
addition, the use of erythropoietin might have reduced
the fatigue in patients who became anemic during the
course of treatment.Today, the regimen we report could
be given on an outpatient basis to most individuals.
Indeed, after the preliminary report of the present
trial,
25 another group also demonstrated the feasibility
of repeating cycles of ifosfamide-containing
chemotherapy to patients with sarcoma every 2 weeks.
26
In a phase II trial at Memorial Sloan-Kettering
Cancer Center, edatrexate induced responses in 13%
of patients with advanced sarcoma.
7 Although the
activity of edatrexate in a National Cancer institute
of Canada trial was marginal,
27 responses have been
seen in an ECOG trial.
8 A high response rate in the
latter trial would provide impetus for further
exploration of the combination of edatrexate and
ifosfamide.
Perhaps the greatest potential for any active drug
or regimen lies in adjuvant therapy. Several
uncontrolled trials
19,20 and one prospective rand-
omized trial
29 suggest that pre-operative or post-
operative anthracycline/ifosfamide combination
chemotherapy regimen results in improved survival
in patients with operable soft tissue sarcoma. Whereas
dose-intense regimens are difficult to apply in
patients with advanced disease, experience in other
diseases documents that vigorous, repetitive
chemotherapy programs can be tolerated by patients
for ® nite periods of time.
30 The present study
demonstrates the feasibility of administering a dose-
intense schedule of ifosfamide alone or ifosfamide
with edatrexate.
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